Twist Bioscience 2026 Q4 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Fiscal 2026 revenue was $459.4 million, up 22% from $376.6 million in fiscal 2025 and more than $30 million above initial fiscal 2026 guidance.
- 4th quarter revenue was $126.6 million, up 28% year over year and 7% sequentially, marking Twist Bioscience’s 15th consecutive quarter of sequential growth.
- Full-year gross margin was 52.4%, compared with 50.7% in fiscal 2025, and 4th quarter adjusted EBITDA was positive $2.2 million; full-year adjusted EBITDA was a loss of $35.9 million.
- DNA synthesis and protein solutions revenue was $61 million in the 4th quarter, up 33% year over year, and $221.9 million for the full year, up 32%.
- NGS applications revenue was $65.7 million in the 4th quarter, up 24% year over year, and $237.5 million for the full year, up 14%.
- AI drug discovery revenue increased 175%, from $21.5 million in fiscal 2025 to $59.1 million in fiscal 2026, while orders more than doubled.
- Twist ended fiscal 2026 with $582 million in cash, cash equivalents, and short-term investments, including $424.8 million in aggregate net proceeds from its public offering and at-the-market program.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Twist Bioscience Fiscal 2026 Fourth Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please advise that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Angela Bitting, SVP of Corporate Affairs. Please go ahead. Thank you, operator.
Good morning, everyone, and thank you for joining us to review Twist Bioscience's Fiscal 2026 Fourth Quarter and Full Year Results and Business Progress. Our earnings release is available at www.twistbioscience.com. With me today are Dr. Emily Leproust, CEO and Co-Founder, Dr. Patrick Finn, President and COO, and Adam Laponis, CFO. We will discuss our business progress, financial and operational performance, and growth opportunities, followed by questions. As a courtesy to others, please limit yourself to one question and then requeue. This call is being recorded. The audio will be archived in the Investor Relations section of our website and available for two weeks. During today's presentation, we will make forward-looking statements within the meaning of the U.S. Federal Securities Laws. These statements generally relate to future events or future financial or operating performance.
Our expectations and beliefs regarding these matters may not materialize, and actual results are subject to risks and uncertainties that could cause them to differ materially from those projected. These risks include those set forth in the press release issued earlier today and those more fully described in our filings with the Securities and Exchange Commission. Our forward-looking statements are based on information available to us today, and we disclaim any obligation to update them except as required by law. We will also discuss adjusted EBITDA, a financial measure that does not conform with generally accepted accounting principles. This measure may be calculated differently from similarly titled measures used by other companies. A reconciliation of historical GAAP and non-GAAP financial measures and information about our forward-looking non-GAAP guidance are included in our earnings materials available in the Investor Relations section of our website.
With that, I will turn the call over to Emily.
Thank you, Angela, and good morning, everyone. Fiscal 2026 was a pivotal year for Twist. We accelerated top-line revenue growth, delivered positive adjusted EBITDA in the fourth quarter, and expanded our capabilities for the opportunities ahead. On slide three, we reported that fourth quarter revenue was $126.6 million, up 28% year-over-year. This is our 15th consecutive quarter of sequential growth. On slide four, full year revenue reached almost $460 million, up 22%, and more than $30 million above our initial 2026 guidance. Over the last three years, revenue grew at a compound annual rate of 23%, with NGS applications growing 24% and DSPS growing 22%. Full year gross margin reached 52.4%. Fourth quarter adjusted EBITDA was positive at $2.2 million, delivering the milestone we committed to several years ago. These results demonstrate the strength of our platform and the discipline of our team.
It took years of work to build and iterate the manufacturing infrastructure we have today. As we scaled our infrastructure, we have also expanded our commercial reach and now serve thousands of customers routinely. Thank you to every Twister who brought us here. Crossing adjusted EBITDA break-even provides us with more options for how we run Twist. We intend to invest our profits in the capabilities, capacity, and people that can drive top-line growth moving forward. On slide five, for those new to Twist, we write DNA on silicon. By miniaturizing the chemistry by 99.8%, we manufacture a million unique DNA sequences in parallel using a very small fraction of the materials required by traditional methods. We believe our proprietary platform gives us a structural advantage in cost, scale, and speed. This enables us to provide customization at scale for our customers.
As healthcare becomes more personalized, we believe the need for custom manufacturing at scale grows exponentially. Twist was built for that future. Our new product introduction, or NPI engine, drives volume onto the tube. Each launch builds on our manufacturing infrastructure, expertise, and commercial reach, allowing us to serve more of our customers' workflows and enter new applications. Over the course of the last several years, through the introduction of new products, our serviceable addressable market has expanded from $2 billion to $7 billion, with line of sight to $13 billion by 2030. Today, our solutions help customers discover medicines, develop diagnostic tests, and advance research across industries. Each new capability expands what customers can do with Twist. AI-enabled drug discovery is a powerful example of our NPI engine at work.
Turning to slide six, as customers use AI to design more molecules to explore more targets, the amount of experimental work they can pursue expands. Those designs need to become physical molecules. The molecules need to be tested, and the results need to be consistent and useful enough to continuously improve model performance. Twist brings those steps together. We manufacture the DNA, express the proteins, and then test those proteins to generate characterization data. Our role becomes more valuable as the numbers of sequences grow and the experiments become more demanding. Because every customer is different, there are many paths they can choose when pursuing AI-enabled drug discovery, and we build Twist to create value across each of them. Customer can buy individual genes or pool DNA and do the experimental work themselves.
They can buy protein and run their own assays, or they can use our full workflow from DNA synthesis through protein expression and characterization. All of these roads lead to Twist. There are multiple ways to access our platform, each creating a revenue opportunity for Twist. We do not need every customer to follow the same path. Every path offers quality, speed, and scale. As AI expands what customers can design, we give them the means to build and test it. Our leadership in this market is built on the ability to execute that work at scale. It is grounded in the manufacturing platform we have spent more than a decade building, and in the capabilities we continue to add on top of our strengths. In fiscal 2026, we expanded automation across the business with a particular focus on protein expression and characterization.
We introduced complex genes, enabling us to accept the vast majority of sequences up to seven kilobases. We licensed the B-Body bispecific technology, a robust platform conducive to our high-throughput automation capabilities. In late October, we launched Twist Express Screening Antibodies, a cell-free offering that delivers proteins in as few as five days and characterization data in as few as eight business days. AI drug discovery delivered an exceptional year. Orders more than doubled, and revenue grew 175% from $21.5 million in fiscal 2025 to $59.1 million in fiscal 2026. Existing customers returned for repeat design, build, test, learn cycles, and new customers chose Twist as their build and test partner. Our reported AI drug discovery revenues for both years reflect the customer we could clearly identify through their orders or set its focus on AI drug discovery.
Over the last 18 months, we have seen a pattern emerge across successive customer cohorts. Customers start with a pilot order, typically from $10,000 to $100,000. They then place model-building orders, often multiple millions of dollars, primarily for characterization data. After digesting the data over a quarter or more, customers return to conduct actual drug discovery, providing novel targets and sequences for us to build and test. These recurring discovery orders typically run from $250,000 to $1 million in iterative cycles until they have the antibodies that are ready to advance to preclinical development. Then they start the process of discovery again with a different target. In general, the run rate revenue for a given customer exceeds model-building revenue, and across the business, we believe we will see significant growth in both model building and discovery for many years to come.
From conversations with customers and potential customers, we believe AI will continue to enhance how drugs are discovered. Based on the same conversations, customers believe they will need more DNA, more protein, and more data to support AI drug discovery, and we believe we are still early in this opportunity. Our customers' funnel continues to grow. The revenue opportunity remains robust, and we expect AI drug discovery to remain one of our fastest-growing product groups in fiscal 2027, with orders momentum accelerating throughout the year. We are seeing the durability of the customer base, with several cohorts of customers returning in a similar pattern. Our focus today is to ensure we have the capacity for the demand we expect is coming. Over the last 12 months, we increased protein and antibody manufacturing capacity by almost 200% and expanded characterization capabilities by two to five times, depending on the assay.
Moving forward, we are significantly expanding capacity across our DNA, protein, and characterization workflows to support larger customer programs and capture growing demand. These investments go beyond adding equipment. We are automating the automation, increasing throughput, and improving turnaround times across the full workflow. We are also adding another characterization lab in our existing Oregon facility as we continue to expand capacity to stay ahead of customer demand. For many of our characterization assays, this means another 5x capacity expansion versus where we existed fiscal 2026, giving us the ability to grow with existing customers, serve new customers, and convert demand into revenue. Turning to slide seven, nucleic acid therapeutics exemplify another large opportunity to expand our platform. These therapies use DNA or RNA to achieve a therapeutic effect.
Researchers working on mRNA, antisense oligonucleotide, and small interfering RNA need to make and evaluate hundreds of thousands to millions of unique sequences. That plays directly to our strength of customization at scale. Personalized cancer therapy illustrates the potential. In one approach under development, researchers identify mutations in a patient's tumor and design mRNA therapeutic sequences intended to help the immune system recognize and attack their unique cancer. Each patient needs many different sequences. Producing those sequences at scale with consistent quality and traceability for our customers who deliver those therapies to patients is directly in line with the challenges Twist was built to address. We already supply DNA templates and siRNA for selected customers, including DNA used in investigational therapies being evaluated in clinical trials.
In fiscal 2026, we expanded complex genes and research-grade DNA preparation options to support more demanding preclinical work, which is the underlying input for advanced mRNA therapeutics. Supplying the materials for companies developing mRNA therapeutics is a natural next step. Today, we offer research-grade mRNA to selected customers through early access, with a high-throughput offering in development. For personalized cancer therapies to reach millions of patients, manufacturing must become faster, more efficient, and more affordable. Our ambition is to bring the economics of our platform to this emerging market, supplying the molecules and manufacturing capabilities our customers need to scale. We are building this opportunity in stages. Early clinical programs generate modest revenue, but supporting customers now positions us to grow with them when their therapies advance, just as we did in liquid biopsy.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
